An interventional study of wPap Mobile Web App Intervention in Cervical Cancer Screening, sponsored by University of South Dakota. Not yet recruiting at 1 site in United States. Open to female participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by University of South Dakota · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 143 open to participants now, 218 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.
Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 256th largest by planned enrollment of the 678 interventional ones that give a count, is one of 30 that started in 2026, is one of 246 with no phase, reaches primary completion later than 47 of the 217 other live ones, and was the 825th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →143 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 30–65 · Women only · Healthy volunteers
Florida A&M University · Sites in United States
Ages 21–65 · Women only · Healthy volunteers
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
Mark Bernard · Sites in United States
Ages 18–99
University of Florida · Sites in United States
Ages 25+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 25 Years to 65 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
834 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 242 · Phase 2 240 · Phase 3 45 · Phase 4 9
First in 1992; this study’s year is marked. 30 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 71 across the 678 interventional studies, 138 across the 124 observational. Of the 570 that completed or were terminated, 193 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 834 have an industry lead sponsor. The 10 most frequent:
University of South Dakota is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
University of South Dakota has 1 study filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
84 of the studies in Uterine Cervical Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT02285192Memorial Sloan Kettering Cancer CenterPositron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer | 2026-11 |
| NCT05758688Abramson Cancer Center at Penn MedicinePROton Therapy for Post Surgical Treatment of GYNecologic Cancer | 2026-11 |
| NCT07574190University of South DakotaA Mobile Web App Intervention to Promote Cervical Cancer Screening | 2026-11 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
Add all 84 to your calendar (.ics) → With an account.
Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overarching goal of this study is to increase cervical cancer (CC) screening rates among Indigenous women in the U.S. Specifically, the study aims to develop and evaluate a culturally tailored, multilevel, multimedia mobile web app intervention (wPap) for women of the Yankton Sioux Tribe (YST) living on the YST Reservation in South Dakota.
The wPap intervention will be tested in a randomized clinical trial (RCT) involving 120 YST women aged 25-65. Participants will be randomly assigned to either: (a) the wPap intervention group (n = 60), receiving personalized, culturally tailored multilevel multimedia messages through a mobile web app along with health navigator support, or (b) a waitlist control group (n = 60), receiving printed educational materials on cervical cancer and screening guidelines along with health navigator support. The intervention will last seven days, with assessments conducted at baseline, one week post-intervention, and six months post-intervention via surveys and telephone follow-up.
The study tests the following hypotheses:
(H1) women in the wPap intervention group will achieve higher CC screening rates than the waitlist control group; (H2) the wPap group will demonstrate greater improvements in knowledge, attitudes/beliefs, self-efficacy, and intention to undergo CC screening; and (H3) the wPap group will report higher satisfaction and acceptance of the intervention compared with the waitlist control group. Findings will inform the feasibility, acceptability, and efficacy of mobile web app interventions tailored to Indigenous communities to improve CC screening.
This study aims to increase cervical cancer (CC) screening among Yankton Sioux Tribe (YST) women by testing a culturally tailored mobile web app intervention called wPap. We plan to enroll 120 eligible women aged 25-65 living on the YST Reservation, anticipating a 20% attrition rate (about 24 participants) by the six-month follow-up. This sample size is based on prior findings from our wMammogram study, which showed a medium effect size for screening interventions. Selecting 120 participants ensures sufficient power to detect meaningful differences between groups, even with attrition.
Participants will be randomly assigned to one of two groups: the wPap intervention group, which receives personalized, culturally tailored multimedia messages through a mobile web app along with health navigator support, or a waitlist control group, which receives printed educational materials and health navigator support. The intervention lasts seven days, and assessments will be conducted at baseline, one week post-intervention, and six months post-intervention.
Outcome Measures:
Data Analysis: Descriptive statistics will summarize participant characteristics, outcomes, and retention. Group equivalence at baseline will be assessed using t-tests and chi-square tests. Chi-square tests and logistic regression will evaluate CC screening completion by intervention group, adjusting for socio-demographic factors. Analyses will be performed using STATA and R.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm will receive a seven-day mobile web app intervention designed to promote cervical cancer (CC) screening. Participants are required to download the wPap mobile app and complete daily educational modules over the seven-day period. Each module includes information about CC risk factors, screening guidelines, and health promotion strategies tailored to the cultural context of the Yankton Sioux Tribe. Participants will complete pre- and post-tests to assess knowledge, attitudes, self-efficacy, and intent to undergo screening. The intervention encourages participants to increase awareness of CC screening needs and supports engagement with available health services.
Behavioral: wPap Mobile Web App Intervention
Participants are randomized to control arm where they are give an education brochure. There are pre and post tests to complete.
A seven-day mobile web app program providing culturally tailored educational modules on cervical cancer risk, screening guidelines, and health promotion strategies. Participants download the app, complete daily modules, and complete pre- and post-tests to assess knowledge, attitudes, self-efficacy, and intention to undergo cervical cancer screening. Health navigator support is provided throughout the intervention.
Receipt of Cervical Cancer Screening
Completion of one of the three recommended screening methods by the ACS: primary HPV testing, co-testing, or Pap test alone. Completion of screening will be assessed using physician-signed verification of CC screening (Yes, No).
Time frame: 6 months
Cervical Cancer Knowledge
Cervical cancer knowledge will be assessed using Taylor et al.'s Cervical Cancer Knowledge Scale, a modified previously validated 15-item true/false instrument. Scores range from 0 to 15, with scores calculated as the total number of correctly answered items. Higher scores indicate greater cervical cancer knowledge and represent a better outcome.
Time frame: Measured at baseline and 1 week post-intervention.
Health Beliefs and Attitudes Toward Cervical Cancer Screening
Health beliefs and attitudes toward cervical cancer screening will be assessed using selected domains from the Champion's Health Belief Model Scale. Four domains consisting of 19 items will be used: perceived susceptibility, perceived seriousness, perceived benefits, and perceived barriers. Scores on the Champion's Health Belief Model Scale range from 1 to 76, with scores calculated by summing item responses within each domain. Higher scores indicate stronger endorsement of the respective health belief construct. Higher scores for perceived susceptibility, perceived seriousness, and perceived benefits represent more favorable beliefs and attitudes toward cervical cancer screening and indicate a better outcome, whereas higher scores for perceived barriers represent less favorable beliefs toward cervical cancer screening and indicate a worse outcome.
Time frame: Measured at baseline and 1 week post-intervention.
Self-Efficacy for Cervical Cancer Screening
Self-efficacy for cervical cancer screening will be assessed using a modified version of Frerichs et al.'s Colorectal Cancer Screening Self-Efficacy Scale, adapted for this study to evaluate participants' confidence in obtaining cervical cancer screening. Scores on the Cancer Screening Self-Efficacy Scale range from 1 to 32, with higher scores indicating greater self-efficacy for completing cervical cancer screening behaviors and representing a better outcome.
Time frame: Measured at baseline and 1 week post-intervention.
Intent to Undergo Cervical Cancer Screening
Intent to undergo cervical cancer screening will be assessed using two items informed by the Transtheoretical Model stages of change, which reflect increasing commitment toward adoption of screening behavior (precontemplation, contemplation, and preparation). The items assess: (1) participants' plan to receive cervical cancer screening in the next 6 months (Yes/No), and (2) level of intention to undergo cervical cancer screening in the future, rated on a 4-point scale ranging from today or within 1 month to within 1 year. Higher scores indicate greater intention and readiness to undergo cervical cancer screening.
Time frame: Measured at baseline and 1 week post-intervention.
Participant Satisfaction With the Intervention
Participant satisfaction with the intervention will be assessed using a single-item satisfaction measure rated on a 4-point Likert scale, with scores ranging from 1 (very dissatisfied) to 4 (very satisfied). Higher scores indicate greater satisfaction with the intervention and represent a better outcome.
Time frame: Measured at 1 week post-intervention.
Participant Acceptance of the Intervention
Participant acceptance of the intervention will be assessed by a single-item measure evaluating willingness to recommend the intervention received to friends (Yes/No). A "Yes" response indicates acceptance and positive endorsement of the intervention.
Time frame: Measured at 1 week post-intervention.
Plan to share: No — Not sharing IPD with other researchers
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Nov 2026, 6 months later.
Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 6 months is below that.
Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of South Dakota